SCHEMBL1937578

SCHEMBL1937578

NCC1CN(Cc2ccccc2)CC1c1ccc(Cl)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.49
CCR5 P51681 5/20 0.48
DPP4 P27487 3/20 0.44
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
DRD2 P14416 2/20 0.40
DRD3 P35462 2/20 0.40
DRD4 P21917 1/20 0.40
SIGMAR1 Q99720 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
GBA1 P04062 1/20 0.39
FUCA1 P04066 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1421756 0.89 RORC (0.52) RORCCCR5DPP4DRD2DRD3
SCHEMBL1421644 0.89 RORC (0.52) RORCCCR5DPP4DRD2DRD3
SCHEMBL1974849 0.89 RORC (0.52) RORCCCR5DPP4DRD2DRD3
SCHEMBL13198817 0.89 RORC (0.52) RORCCCR5DPP4DRD2DRD3
SCHEMBL1976030 0.89 RORC (0.52) RORCCCR5DPP4DRD2DRD3
SCHEMBL7878252 0.89 RORC (0.52) RORCCCR5DPP4DRD2DRD3
SCHEMBL1507367 0.86 RORC (0.47) RORCCCR5DPP4DRD2DRD3
SCHEMBL1507381 0.86 RORC (0.47) RORCCCR5DPP4DRD2DRD3
SCHEMBL1507371 0.86 RORC (0.47) RORCCCR5DPP4DRD2DRD3
SCHEMBL1974964 0.85 RORC (0.49) RORCCCR5DPP4HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364295-B1 3-(BENZYLAMINO)-PYRROLIDINE DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-02-27 EP disclosed
US-8293770-B2 Pyrrolidine derivatives as NK-3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-10-23 US disclosed
US-8022099-B2 N-benzyl pyrrolidine derivatives HOFFMANN-LA ROCHE INC. (US) 2011-09-20 US disclosed
EP-2364295-A1 3-(BENZYLAMINO)-PYRROLIDINE DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-09-14 EP disclosed
EP-2331500-A1 PYRROLIDINE N-BENZYL DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-06-15 EP disclosed
US-20100168088-A1 PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 US disclosed
WO-2010060703-A1 3-(BENZYLAMINO)-PYRROLIDINE DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-06-03 WO disclosed
US-20100113424-A1 N-BENZYL PYRROLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 US disclosed
WO-2010040663-A1 PYRROLIDINE N-BENZYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168088-A1 PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS OPRK1, OPRL1, OPRD1 RORC 806/4885CCR5 934/4885DPP4 2359/4885
US-20100113424-A1 N-BENZYL PYRROLIDINE DERIVATIVES OPRK1, OPRD1, OPRL1 RORC 730/4885CCR5 1534/4885DPP4 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.